Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Savara, Inc. Selected As Texas Emerging Technology Fund Recipient

Abstract:
The Austin Chamber of Commerce and the Central Texas Regional Center of Innovation and Commercialization (CenTex RCIC) announce that the state of Texas has chosen Savara, Inc. as the recipient of a commercialization award funded through the Texas Emerging Technology Fund (ETF). This company, which produces novel respiratory therapeutics, will receive a $1.9 million award for the commercialization of its products.

Savara, Inc. Selected As Texas Emerging Technology Fund Recipient

Austin, TX | Posted on June 16th, 2010

"Savara's dry-powder technology holds great potential for treating asthma, lung cancer, and other lung based diseases," said Jack McDonald Chairman of Perficient, Inc. and Chairman of the CenTex RCIC. "This investment by the ETF will not only help grow our biotech industry in Central Texas but may result in new therapies that save lives."

Savara is an inhalation drug development company developing next generation respiratory therapeutics utilizing its proprietary NanoCluster dry-powder formulation technology. NanoCluster's unique features can produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience.

"Texas is a leader in cutting edge biotechnologies thanks to investments from the Texas Emerging Technology Fund that have attracted companies and top researchers to our state," said Gov. Rick Perry. "Savara's technology will help identify and treat lung cancer more quickly and efficiently, saving lives and bringing us one step closer to eliminating this deadly disease."

This award will be used to advance the development of Savara's lead project towards Investigational New Drug (IND) approval.

"We are very excited and honored to have been named a Texas Emerging Technology Fund recipient," said Rob Neville, CEO of Savara, Inc. "This milestone is important to Savara as we are now able to progress our lead therapy into the clinic."

Currently, Savara plans to provide 12 jobs directly and three to five jobs indirectly through the year 2013. Savara has established an important collaboration with the Austin Technology Incubator (ATI) at the University of Texas at Austin where it continues to develop its drug delivery platform and products.

"This new biomedical technology brings about exciting possibilities for local treatment of serious lung diseases," said Isaac Barchas, Director, ATI. "The Technology Incubator is eager to continue our collaboration with Savara and this investment from the ETF will allow that to happen."

Savara, Inc. was selected by the CenTex RCIC after an extensive due diligence process based on multiple criteria including a stringent analyses of the market and financial opportunity, technology potential, management team and economic impact to Texas.

The CenTex RCIC is a virtual center that operates out of the Austin Chamber of Commerce and serves as a catalyst for emerging technology research, development, commercialization and start-up incubation. In an effort to keep Texas globally competitive, the CenTex RCIC focuses on integrating technology development and commercialization in a 15-county region.

####

About Savara
Savara, Inc. (www.savarapharma.com) is an inhalation drug development company developing next generation respiratory therapeutics utilizing its proprietary NanoCluster dry-powder formulation technology. Savara’s NanoCluster technology is currently available for evaluation and licensing.

About Savara’s NanoCluster Technology
Particle size is critical for pulmonary drug delivery, and the ability to obtain particle sizes in the range of 1-3 microns has the potential to improve the efficacy of existing and new drug therapies. Savara’s NanoCluster technology utilizes nanotechnology to formulate high performance inhalation powder without the need for novel excipients or carrier particles. Savara’s NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung. These aerodynamics enable high drug concentrations in specific regions of the lung, independent of the inhalation flow rate. Savara expects that NanoCluster’s unique features will enable products that are currently difficult or impossible to develop using conventional inhalation powders.

For more information, please click here

Contacts:
Savara, Inc.
3925 West Braker Lane
Austin, Texas 78759


Corporate
Toll Free: (888) 302-4876
Telephone: (512) 961-1891
Fax: (512) 305-0009

Copyright © Savara

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

UCLA chemists synthesize narrow ribbons of graphene using only light and heat: Tiny structures could be next-generation solution for smaller electronic devices December 8th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Jobs

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Participate in the development of Malaysia’s National Graphene Action Plan 2020 October 10th, 2016

Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016

SUNY Poly Welcomes DPS as the Global Engineering Firm Opens Its U.S. Advanced Technology Group Headquarters at Cutting-Edge ZEN Building November 20th, 2015

Govt.-Legislation/Regulation/Funding/Policy

Wheat gets boost from purified nanotubes: Rice University toxicity study shows plant growth enhanced by -- but only by -- purified nanotubes December 6th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Chinese market opens up for Carbodeon nanodiamonds: Carbodeon granted Chinese Patent for Nanodiamond-containing Thermoplastic Thermal Compounds December 4th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

Nanomedicine

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

Announcements

Leti Develops World’s First Micro-Coolers for CERN Particle Detectors: Leti Design, Fabrication and Packaging Expertise Extends to Very Large Scientific Instruments December 11th, 2017

UCLA chemists synthesize narrow ribbons of graphene using only light and heat: Tiny structures could be next-generation solution for smaller electronic devices December 8th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Nanobiotechnology

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Going swimmingly: Biotemplates breakthrough paves way for cheaper nanobots: By using bacterial flagella as a template for silica, researchers have demonstrated an easier way to make propulsion systems for nanoscale swimming robots November 30th, 2017

Drug-delivering nanoparticles seek and destroy elusive cancer stem cells November 28th, 2017

Graphene oxide making any material suitable to create biosensors: Scientists from Tomsk Polytechnic University have developed a new tool for biomedical research focused on single-cell investigation November 27th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project